Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback